Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection

Yan Guo a, Lei He b, Nianping Song a, Pei Li a, Shihui Sun a, Guangyu Zhao a, Wanbo Tai a,c, Shibo Jiang c, Lanying Du c,**, Yusen Zhou a,b,*

a State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
b Graduate School of Guangxi Medical University, Nanning, Guangxi, China
c Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA

Received 1 August 2017; accepted 31 August 2017
Available online 10 September 2017

Abstract

Highly pathogenic influenza viruses continue to cause serious threat to public health due to their pandemic potential, calling for an urgent need to develop effective, safe, convenient, and universal vaccines against influenza virus infection. In this study, we constructed two recombinant protein vaccines, 2H5M2e-2H7M2e-H5FP-H7FP (hereinafter M2e-FP-1) and 2H5M2e-H5FP-2H7M2e-H7FP (hereinafter M2e-FP-2), by respectively linking highly conserved sequences of two molecules of ectodomain of M2 (M2e) and one molecule of fusion peptide (FP) epitope of hemagglutinin (HA) of H5N1 and H7N9 influenza viruses in different orders. The Escherichia coli-expressed M2e-FP-1 and M2e-FP-2 proteins induced similarly high-titer M2e-FP-specific antibodies in the immunized mice. Importantly, both proteins were able to prevent lethal challenge of heterologous H1N1 influenza virus, with significantly reduced viral titers and alleviated pathological changes in the lungs, as well as increased body weight and complete survivals, in the challenge mice. Taken together, our study demonstrates that highly conserved M2e and FP epitope of HA of H5N1 and H7N9 influenza viruses can be used as important targets for development of safe and economical universal influenza vaccines, and that the position of H7N9 M2e and H5N1 HA epitope sequences in the vaccine components has no significant effects on the immunogenicity and efficacy of M2e-FP-based subunit vaccines.

© 2017 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Keywords: Influenza virus; M2e; Hemagglutinin fusion peptide; Universal vaccines; Protection

1. Introduction

Influenza is one of the important emerging infectious diseases threatening public health worldwide. Influenza vaccines are required annually to immunize a large number of people to prevent influenza. The highly pathogenic avian influenza viruses H5N1 and H7N9, as well as 2009 pandemic H1N1 influenza virus, have infected humans and caused sporadic cases or epidemics [1–9], calling for continuous efforts to develop vaccines to prevent the threat of influenza. Current influenza vaccines are mainly strain-specific, targeting one or more closely related strains, and having limited efficacy to prevent divergent and new viral strains [10–12]. Thus, development of effective universal vaccines with cross-protective efficacy against variant influenza viruses has been the focus of influenza researches.

The extracellular domain of M2 (M2e) protein of influenza virus is highly conserved among all influenza A viruses, thus serving as a promising target for developing universal influenza vaccines [13,14]. However, containing only 24 amino
acids, the M2e molecule is a poor inducer of immune response, elucidating the need to improve its immunogenicity in designing influenza vaccines. A number of approaches, including conjugating M2e with other carrier proteins, such as Neisseria meningitidis outer membrane complex (OMPC) and bacterial flagellin, or increasing the copy numbers of M2e molecules, have been introduced to increase the immunogenicity and/or protective efficacy of M2e-based vaccines [15−19]. In addition to M2e, fusion peptide (FP) epitope in the hemagglutinin 2 (HA2) stem region of influenza virus is also highly conserved in influenza A viruses, making it as another important vaccine target [14,20,21]. Chimeric vaccines or synthetic peptides containing conserved HA2 sequences may induce cross-reactive and cross-protective antibodies against divergent influenza viruses [22−24], constituting a key approach to develop universal influenza vaccines.

In this study, we designed two recombinant vaccines, 2H5M2e-2H7M2e-H5FP-H7FP (hereinafter M2e-FP-1) and 2H5M2e-2H5FP-2H7M2e-H7FP (hereinafter M2e-FP-2), respectively containing highly conserved sequences of two M2e molecules and one HA-FP molecule of H5N1 and H7N9 influenza viruses in two different orders, and expressed the proteins in Escherichia coli expression system. We further evaluated the immunogenicity and cross-protective efficacy of these two subunit vaccines against a heterologous strain of H1N1 influenza virus. This study demonstrates that the position of H7N9 M2e and H5N1 HA epitope sequences in the vaccine components has no significant impact on the immunogenicity and efficacy of M2e-FP-based subunit vaccines, suggesting the potential to develop these proteins as effective and economical universal influenza vaccines.

2. Materials and methods

2.1. Ethics statement

Female BALB/c mice at 6−8 weeks old were used in the study. The animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocols were approved by the Committees on the Ethics of Animal Experiments of the Beijing Institute of Microbiology and Epidemiology (Permit Number: PMB15-0012), and the New York Blood Center (Permit Number: 322.06).

2.2. Construction of recombinant vaccines

The construction of recombinant vaccines containing M2e and HA-FP of H5N1 and H7N9 influenza viruses was carried out as previously described [25]. Briefly, genes encoding the highly conserved sequences of two molecules of H5N1 M2e and one molecule of HA-FP, as well as two molecules of H7N9 M2e and one molecule of HA-FP, in two orders were synthesized, inserted into pQE30 E. coli Expression Vector, and sequenced for corrected sequences. A linker sequence encoding GGGS was added between each molecule, and a His$_6$ tag was added at the C-terminus for easy purification of expressed recombinant proteins.

2.3. Recombinant protein expression and purification

The recombinant M2e-FP-1 and M2e-FP-2 proteins were expressed in the E. coli expression system as previously described [25,26] with some modifications. Briefly, the aforementioned recombinant plasmids encoding M2e-FP-1 and M2e-FP-2 proteins were transformed into E. coli (M15), cultured in LB medium overnight at 37 °C, diluted (1:100), and then continuously cultured until the OD600 value reaching 0.6−1.0. Isopropyl-β-D-thiogalactopyranoside (IPTG, Sigma) was added at the final concentration of 1 mM, and the E. coli was centrifuged to collect pellets. The sonicated E. coli supernatant containing the expressed proteins was collected, and purified using Ni-chromatography (Promega) and gel filtration chromatography. The purified recombinant proteins were concentrated, analyzed for endotoxin, and used for further studies.

2.4. SDS-PAGE and Western blot

The recombinant M2e-FP-1 and M2e-FP-2 proteins were analyzed by SDS-PAGE and Western blot as previously described [27,28]. Briefly, the IPTG-induced proteins and non-induced controls were boiled for 10 min, separated by 10% Tris–Glycine gels, and stained with Coomassie Brilliant Blue for SDS-PAGE analysis. The same samples were also transferred to nitrocellulose membranes for Western blot analysis by blocking the blots using 5% fat-free milk in PBST overnight at 4 °C, and sequentially incubating them for 1 h at room temperature with influenza virus M2e-specific polyclonal antibodies (1:1000) (laboratory stock), and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (1:5,000, Invitrogen). The signals were then detected using ECL substrate buffer (Pierce) and Amersham Hyperfilm.

2.5. Mouse immunization and virus challenge

A/PR/8/34(H1N1) influenza virus was grown in the allantoic cavities of 9-day-old embryonated chicken eggs. Virus-containing allantoic fluid was harvested after 72 h, and stored at −80 °C until use. Mice were immunized with recombinant proteins and challenged with influenza virus using previously described protocols [27,29] with some modifications. Briefly, BALB/c mice were intramuscularly (i.m.) immunized with M2e-FP-1 or M2e-FP-2 (10 μg/50 μl/mouse) in the presence of aluminum adjuvant, and boosted twice at a 3-week interval. Mice injected with PBS plus above adjuvant were included as a negative control. Sera were collected before each vaccination, and measured for influenza virus M2e-FP-specific IgG, IgG1, and IgG2a antibodies. One month post-last immunization, mice were challenged with A/PR/8/34(H1N1) influenza virus (10$^3$ 50% tissue culture infectious dose: TCID$_{50}$). The infected mice were then detected for
pathological changes by H&E staining and viral titers in lung tissues at 5 days post-infection (p.i.), or observation of survivals and weight changes for 14 days p.i.

2.6. ELISA

ELISA was used to analyze influenza virus M2e-FP-specific antibody responses in the immunized mouse sera as previously described [27,30] with some modifications. Briefly, ELISA plates were coated with recombinant M2e-FP proteins overnight at 4 °C, and blocked with 3% BSA-PBS for 2 h at 37 °C. Mouse sera at 2-serial dilutions were added to the plates, and incubated for 1 h at 37 °C. After 4 washes, the plates were incubated with HRP-conjugated anti-mouse IgG, anti-mouse IgG1, and anti-mouse IgG2a (1:5,000, Santa Cruz), respectively, for 1 h at 37 °C. The reaction was detected by 3,3',5,5'-tetramethylbenzidine (TMB) substrate (Invitrogen), and stopped by 1 N H2SO4. The absorbance at 450 nm was measured using ELISA plate reader, and the related antibody titers were calculated.

2.7. Viral titer detection

Viral titers in lung tissues of the above challenged mice were detected as previously described [25,31] with some modifications. Briefly, lung tissues were homogenized in minimal essential medium (MEM) to achieve 10% (w/v) suspensions. Serially diluted samples were added to monolayers of Madin–Darby canine kidney (MDCK) cells seeded in 96-well tissue culture plates, and incubated for 2 h at 37 °C. Supernatants were removed and replaced with fresh MEM, followed by incubation of MDCK cells for 72 h. Viral cytopathic effect (CPE) was observed daily, and viral titers were calculated by HA test. For the HA test, 50 μl of 0.5% turkey red blood cells (Lampire Biological Laboratories) was added to 50 μl of cell culture supernatant, and incubated at room temperature for 30 min. Wells containing HA were scored as positive. The viral titer was calculated by the Reed and Muench method, and expressed as Log10 TCID50/g of lung tissues.

2.8. Statistical analysis

The values are presented as mean with standard deviation (SD). Statistical significance was calculated by Student’s t-test using GraphPad Prism statistical software. *** indicates P < 0.001.

3. Results

3.1. Construction and characterization of recombinant proteins containing highly conserved M2e and HA-FP epitope of H5N1 and H7N9 influenza viruses

The amino acid sequences of M2e and HA-FP of H5N1, H7N9, H1N1, and H3N2 influenza viruses are highly conserved among all influenza A viruses, maintaining at least 90% homology [14]. Here, we constructed two recombinant proteins, designated M2e-FP-1 and M2e-FP-2, by respectively linking two M2e molecules and one FP epitope of HA protein of H5N1 and H7N9 influenza viruses in different orders (Fig. 1A–B), and expressed the fusion proteins in E. coli expression system, a convenient and economical system for expressing recombinant proteins with manufacture capacity [32–34]. The proteins with the expected molecular weight size were expressed in the soluble form of the induced E. coli (Fig. 1C, left), and purified with 98.6% purity, which were recognized by M2e-specific monoclonal antibodies developed in our laboratories, while no such bands were detected in the non-induced cell controls (Fig. 1C, middle). The purified M2e-FP-1 and M2e-FP-2 proteins were used as coating antigens to detect their reactivity with sera of mice immunized with M2e or FP peptides of influenza virus H5N1 and H7N9. The results showed that these recombinant proteins reacted specifically with the respective sera, but not with the control sera (Fig. 1C, right). These data suggest that the constructed M2e and HA-FP fusion proteins were successfully expressed and maintained strong specificity to influenza virus.

3.2. Immunogenicity of recombinant proteins containing highly conserved M2e and HA-FP epitope of H5N1 and H7N9 influenza viruses

To evaluate the immunogenicity of the M2e and HA-FP fusion proteins, we immunized mice using the two proteins following the protocol described in Materials and Methods, and detected the resulting antibody responses in the mouse sera. As shown in Fig. 2A, both proteins were able to elicit similarly levels of potent M2e-FP-specific IgG antibodies, increased to a higher titer after each boost, and maintained for at least 9 weeks during the detection period, whereas only a background level of antibodies were detected in the sera of the control mice. Further evaluation of antibody subtypes revealed that high titers of M2e-FP-specific IgG2a (Th1), particularly IgG1 (Th2), antibodies were induced in the sera of protein-immunized mice collected at 9 weeks post-immunization, but not in those of the control mice injected with PBS (Fig. 2B–C). The above results indicate that M2e-FP-1 and M2e-FP-2 maintained strong immunogenicity in inducing long-term specific antibodies, and that both fusion proteins elicited a relatively higher titer of Th2 (IgG1)-biased antibody response, thus potentially promoting the production of antibody-mediated humoral immune response.

3.3. Recombinant proteins containing highly conserved M2e and HA-FP epitope of H5N1 and H7N9 influenza viruses significantly reduced viral replication and pathological changes

Having confirmed the immunogenicity of M2e-FP1 and M2e-FP-2 fusion proteins, next we investigated their protective immunity by challenging the immunized mice with a heterologous strain of A/PR/8/34(H1N1) influenza virus, and detected viral replication and pathological damage in the lungs.
at 5 days post-infection. As expected, mice immunized with the two fusion proteins had significantly lower titers of virus in their lungs than those of the control mice receiving PBS (Fig. 3A). Analysis of the pathological changes demonstrated that both fusion proteins effectively protected mice against H1N1 infection, with obviously alleviated lung damage and the presence of BALT (bronchus-associated lymphoid tissue) surrounding the lung bronchial tube (Fig. 3B, left and middle), a characteristic helping for restoring lung tissue cells. In contrast, there was serious mesenchymal inflammation in the lung tissue of the control mice, which was represented by thickened alveolar walls, inflammatory cell infiltration, hemorrhage, and vessel inflammation (Fig. 3B, right). The above data suggest that the two fusion proteins had strong ability to inhibit viral replication and reduce virus-caused tissue damage.

3.4. Recombinant proteins containing highly conserved M2e and HA-FP epitope of H5N1 and H7N9 influenza viruses completely protected against heterologous challenge

The protective efficacy of M2e-FP fusion proteins were further evaluated by challenging the immunized mice with A/
PR/8/34(H1N1) influenza virus, and recording mouse survivals and weight changes for up to 14 days post-challenge. The results demonstrated that both M2e-FP-1 and M2e-FP-2 significantly prevented weight loss of the mice after viral challenge, with slightly reducing weights during 3–5 days, and then steadily increasing weights at 6 days, post-infection. By comparison, the control mice had a continuous weight loss (Fig. 4A). In addition, all mice immunized with the two fusion proteins survived from influenza virus challenge at the end of the detection period, whereas none of the control mice injected with PBS survived from such challenge, all of which died by 11 days post-infection (Fig. 4B). These results confirm the protective efficacy of the test influenza vaccines in providing complete protection against infection of heterologous strain of influenza virus, suggesting that the position of H7N9 M2e and H5N1 HA-FP epitope sequences in the M2e-FP-based subunit vaccines had no significant impact on the protection.

4. Discussion

The highly conserved influenza virus M2e and FP of HA2 can be used as effective vaccine targets to develop universal influenza vaccines with broad protective efficacy to prevent against divergent viral strains [12,14,35]. Indeed, we have previously indicated that a tetra-branched multiple antigenic peptide (MAP)-based vaccine (H5N1-M2e-MAP) carrying four copies of H5N1 M2e peptide conferred cross-protection against lethal infection of two clades of H5N1 and one pandemic 2009 H1N1 influenza viruses [31,36]. We have also demonstrated the ability of a recombinant fusion protein (M2e3-ASP-1) containing three conserved H5N1 M2e molecules and a new Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant in cross-protection against two divergent strains of H5N1 influenza viruses [25]. In addition, H5N1 M2e peptide-based vaccines were developed to test the cross-protection of H5N1 M2e against infection of the new H7N9 virus, and the H5N1 M2e vaccination provided potent cross-protection against lethal challenge of H7N9 virus [37,38]. In this study, we designed two recombinant universal influenza vaccines by respectively linking two molecules of M2e and one molecule of HA-FP sequences of H5N1 and H7N9 in two different orders, and evaluated their immunogenicity and protection against a heterologous H1N1 strain. The sequences of M2e and HA-FP used in this study are highly conserved among all influenza A virus strains, maintaining over 90% homology. As expected, both proteins linked through two different orders of M2e and FP molecules were able to induce effective antibody responses and cross-protection against lethal challenge of A/PR/8/34(H1N1) influenza virus with 100% survival rate, indicating that H5N1 and H7N9 M2e and HA-FP recombinant protein-based universal vaccines have capacity to elicit sufficient cross-protective efficacy against infection of heterologous strain of H1N1 influenza virus.

We have also found that while the two proteins, in the presence of aluminum adjuvant, elicited high titers of antibody response in the immunized mice, they failed to induce
effective cellular immune response (data not shown), suggesting that M2e and HA-FP recombinant protein-induced protection might be mainly through humoral, rather than cellular, immune response-mediated immunity. Studies have shown that the mechanisms of cross-protection by influenza virus M2e-based vaccines may be through antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytolyis (CDC) [39,40]. In addition to M2e molecules, our recombinant proteins also contain HA-FP conserved epitope sequences. Future studies are warranted to further elucidate the protective mechanisms of M2e and HA-FP-based recombinant vaccines, as well as to detect their efficacy in protecting against multiple current and future strains of influenza virus with pandemic potential.

Overall, this study suggests that simultaneous expression of M2e molecule and HA-FP peptide from several important influenza virus strains may help facilitate the development of universal vaccines with broad-spectrum cross-protective efficacy against divergent heterologous strains of influenza viruses, and that the order of M2e and HA-FP in the vaccine components has no significant effects on the immunogenicity and protective efficacy. Our data demonstrate the potential for further development of a universal influenza vaccine based on highly conserved sequences of M2e and HA-FP epitope of influenza virus.

Conflict of interest statement

The authors declared no conflict of interest.

Acknowledgments

This study was supported by Research Grant from Ministry of Health of China (AWS15J006), NIH grant (R21AI111152), and the intramural fund of New York Blood Center (NYB000414).

References

[1] Fineberg HV. Pandemic preparedness and response — lessons from the H1N1 influenza of 2009. N Engl J Med 2014;370:1335–42.
[2] Rewar S, Mirdha D, Rewar P. Treatment and prevention of pandemic H1N1 influenza. Ann Glob Health 2015;81:645–53.
[3] Zhou L, Tan Y, Kang M, Liu F, Ren R, Wang Y, et al. Preliminary epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus, China, 2017. Emerg Infect Dis 2017;23:1355–9.
[4] Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis 2017;17:822–32.
[5] Kang M, Lau EHY, Guan W, Yang Y, Song T, Cowling BJ, et al. Epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus in Guangdong, 2016 to 2017. Euro Surveill 2017;22.
World Health Organization. Human infection with avian influenza A(H7N9) virus — China. Geneva, Switzerland: World Health Organization; 19 July 2017. http://www.who.int/csr/don/19-july-2017-ah7n9-china/en/.

World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2017. Geneva, Switzerland: World Health Organization; 15 June 2017. http://www.who.int/influenza/human_animal_interface/2017_06_15_tableH5N1.pdf.

Normile D. Bird flu strain taking a toll on humans. Science; 17 Feb. 2017. http://www.sciencemag.org/news/2017/02/bird-flu-strain-taking-toll-humans.

Hoessler K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe 2015;17:295–300.

Krammer F, Garcia-Sastre A, Palese P. Is it possible to develop “universal” influenza virus vaccine? Toward a universal influenza virus vaccine: potential target antigens and critical aspects for vaccine development. Cold Spring Harb Perspect Biol 2017. pii: a028845.

Soema FC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 2015;94:251–63.

Fiers W, De Fillette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, et al. M2e-based universal influenza A vaccine. Vaccine 2009;27:6280–3.

Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccination. Cold Spring Harb Perspect Biol 2017. pii: a028845.

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 2010;107:18979–84.

Zhao G, Du L, Xiao W, Sun S, Lin Y, Chen M, et al. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchoerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010;28:7233–40.

Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009;393:144–50.

Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, et al. Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol 2017;91: e01651-16.

Du L, Tai W, Yang Y, Zhao G, Zhu Q, Sun S, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun 2016;7. 13473.

Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipепtide methylid 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 2016;499:375–82.

Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, et al. Identification of an ideal adjuvant for receptor-binding-domain-based subunit vaccines against middle east respiratory syndrome coronavirus. Cell Mol Immunol 2016;13:180–90.

Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010;7:9.

Heikila J. What intravenous treatment for myocardial infarction: beta-blockers, nitrates or thrombolysis? Duodecim 1990;106:79–98.

Rosano GL, Ceccharelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 2014;5:172.

Jia B, Jeon CO. High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives. Open Biol 2016;6.

Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect 2017;23:222–8.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010;7:151.

Leung HC, Chan CC, Poon VK, Zhao HJ, Cheung CY, Fai N, et al. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus. Emerg Microbes Infect 2015;4:e22.

Hasan N, Ebrahimie E, Ignjatovic J, Tarigan S, Peaston A, Hemmatzadeh F. Epitope mapping of avian influenza M2e protein: different species recognise various E. PLoS One 2016;11:e0156418.

Lee YN, Kim MC, Lee YT, Kim YI, Kang SM. Mechanisms of cross-protection by influenza virus M2-based vaccines. Immune Netw 2015;15:213–21.

Kolpe A, Scheppens B, Fiers W, Saelsens X. M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines 2017;16:123–36.